Skip to main content

Senseonics Holdings, Inc.

corporate_fare Company Profile

Senseonics Holdings, Inc.

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

Exchange: NASDAQSector: Industrial Applications And Services

show_chartPrice Chart

Loading chart...

feed SENS - Latest Insights

SENS
Apr 06, 2026, 5:18 PM EDT
Filing Type: DEF 14A
Importance Score:
8
SENS
Mar 27, 2026, 5:04 PM EDT
Filing Type: PRE 14A
Importance Score:
9
SENS
Mar 12, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
SENS
Mar 12, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
SENS
Mar 02, 2026, 4:37 PM EST
Filing Type: 10-K
Importance Score:
8
SENS
Mar 02, 2026, 4:33 PM EST
Source: Wiseek News
Importance Score:
8
SENS
Mar 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
9
SENS
Jan 12, 2026, 8:25 AM EST
Filing Type: 8-K
Importance Score:
8